Baucus Examines Medtronic's GPO Contract Cancellations
This article was originally published in The Gray Sheet
Executive Summary
Sen. Max Baucus is investigating Medtronic's decision earlier this year to cancel several large contracts with hospital group purchasing organizations out of concerns that the firm's actions could increase costs and reduce price transparency in the health care system.
You may also be interested in...
Dropping GPOs: Medtronic's Hawkins Expects More Of It From MedTech
Medtronic CEO Bill Hawkins says he would be "shocked" if some competitors did not follow his firm's lead this year with cancellations of large group purchasing organization contracts.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.